Literature DB >> 10617684

Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide.

T Nagatomo1, C T January, J C Makielski.   

Abstract

Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings. Flecainide (1-300 mM) caused tonic and use-dependent block (UDB) of I(Na) in a concentration-dependent manner. Compared with WT, DeltaKPQ I(Na) was more sensitive to flecainide, and flecainide preferentially inhibited late I(Na) (mean current between 20 and 23.5 ms after depolarization) compared with peak I(Na). The IC(50) value of peak and late I(Na) for WT was 127 +/- 6 and 44 +/- 2 microM (n = 20) and for DeltaKPQ was 80 +/- 9 and 19 +/- 2 microM (n = 31) respectively. UDB of peak I(Na) was greater and developed more slowly during pulse trains for DeltaKPQ than for WT. The IC(50) value for UDB of peak I(Na) for WT was 29 +/- 4 microM (n = 20) and for DeltaKPQ was 11 +/- 1 microM (n = 26). For DeltaKPQ, UDB of late I(Na) was greater than for peak I(Na). Recovery from block was slower for DeltaKPQ than for WT. We conclude that DeltaKPQ interacts differently with flecainide than with WT, leading to increased block and slowed recovery, especially for late I(Na). These data provide insights into mechanisms for flecainide block and provide a rationale at the cellular and molecular level that open channel block may be a useful pharmacological property for treatment of LQT3.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10617684

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  44 in total

1.  Pharmacology and Toxicology of Nav1.5-Class 1 anti-arrhythmic drugs.

Authors:  Dan M Roden
Journal:  Card Electrophysiol Clin       Date:  2014-12-01

Review 2.  Genetic basis for the origin of cardiac arrhythmias: implications for therapy.

Authors:  Mackenzi Mbai; Sridharan Rajamani; Brian P Delisle; Blake D Anson; Corey Anderson; Jonathan C Makielski; Craig T January
Journal:  Curr Cardiol Rep       Date:  2002-09       Impact factor: 2.931

3.  Blocking Scn10a channels in heart reduces late sodium current and is antiarrhythmic.

Authors:  Tao Yang; Thomas C Atack; Dina Myers Stroud; Wei Zhang; Lynn Hall; Dan M Roden
Journal:  Circ Res       Date:  2012-06-20       Impact factor: 17.367

4.  Y1767C, a novel SCN5A mutation, induces a persistent Na+ current and potentiates ranolazine inhibition of Nav1.5 channels.

Authors:  Hai Huang; Silvia G Priori; Carlo Napolitano; Michael E O'Leary; Mohamed Chahine
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-12       Impact factor: 4.733

5.  Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial.

Authors:  Arthur J Moss; John R Windle; W Jackson Hall; Wojciech Zareba; Jennifer L Robinson; Scott McNitt; Patricia Severski; Spencer Rosero; James P Daubert; Ming Qi; Michael Cieciorka; Allan S Manalan
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-10       Impact factor: 1.468

Review 6.  The risk of cardiac events and genotype-based management of LQTS patients.

Authors:  Grazyna Markiewicz-Łoskot; Ewa Moric-Janiszewska; Urszula Mazurek
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-01       Impact factor: 1.468

Review 7.  Genotype-specific risk stratification and management of patients with long QT syndrome.

Authors:  Alon Barsheshet; Olena Dotsenko; Ilan Goldenberg
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-11-08       Impact factor: 1.468

8.  SCN5A (NaV1.5) Variant Functional Perturbation and Clinical Presentation: Variants of a Certain Significance.

Authors:  Brett M Kroncke; Andrew M Glazer; Derek K Smith; Jeffrey D Blume; Dan M Roden
Journal:  Circ Genom Precis Med       Date:  2018-05

9.  Long QT syndrome: from channels to cardiac arrhythmias.

Authors:  Arthur J Moss; Robert S Kass
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

10.  The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome.

Authors:  Naomasa Makita; Elijah Behr; Wataru Shimizu; Minoru Horie; Akihiko Sunami; Lia Crotti; Eric Schulze-Bahr; Shigetomo Fukuhara; Naoki Mochizuki; Takeru Makiyama; Hideki Itoh; Michael Christiansen; Pascal McKeown; Koji Miyamoto; Shiro Kamakura; Hiroyuki Tsutsui; Peter J Schwartz; Alfred L George; Dan M Roden
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.